Literature DB >> 30181932

A Patient with Artifactually Low Serum High Density Lipoprotein Cholesterol Due to Waldenstrom Macroglobulinemia.

Amir Shahbaz1, Kashif Aziz1, Muhammad Umair2, Paria Zarghamravanbakhsh3, Issac Sachmechi1.   

Abstract

When very low or undetectable high density lipoprotein (HDL)-cholesterol (HDL-C) is encountered in clinical practice, a paraproteinemia should be suspected in the absence of genetic or more obvious secondary causes. We reported a case of artifactually low HDL-C in a 68-year-old man with a past medical history of vitamin B12 deficiency. Lipid panel showed total cholesterol (TC) 144 mg/dl, triglycerides (TG) 79 mg/dl, HDL-C 5 mg/dl, and low density lipoprotein (LDL) 123 mg/dl. HDL-C, which was determined three years prior to this presentation was found normal. The patient was prescribed extended release nicotinic acid. Further workup performed showed the ratio of APO B/APO A1 0.36 and direct LDL 28 mg/dl. In the absence of genetic or more obvious secondary causes, we hypothesized that low HDL-C in this patient was due to paraprotein interference in vitro with the liquid homogenous HDL assay. Serum protein electrophoresis demonstrated normal IgG and IgA and an abnormally high IgM at 3510 mg/dl (57-266). A bone marrow biopsy revealed Waldenstrom macroglobulinemia. A diagnostic workup for an isolated low HDL-C unmasking the diagnosis of Waldenstrom macroglobulinemia has been rarely reported. Care must be taken when using the homogeneous method for direct measurement of HDL-C as artifactually undetectable HDL-C might result in the mismanagement of patients with paraproteinemia.

Entities:  

Keywords:  hdl; paraproteinemia; waldenstrom macroglobulinemia

Year:  2018        PMID: 30181932      PMCID: PMC6118291          DOI: 10.7759/cureus.2900

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  7 in total

Review 1.  Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature.

Authors:  M Berth; J Delanghe
Journal:  Acta Clin Belg       Date:  2004 Sep-Oct       Impact factor: 1.264

2.  Historical milestones in measurement of HDL-cholesterol: impact on clinical and laboratory practice.

Authors:  Michel R Langlois; Victor H Blaton
Journal:  Clin Chim Acta       Date:  2006-03-31       Impact factor: 3.786

3.  Severe acquired (secondary) high-density lipoprotein deficiency.

Authors:  Ronald B Goldberg; Armando J Mendez
Journal:  J Clin Lipidol       Date:  2007-02-15       Impact factor: 4.766

4.  Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein.

Authors:  Li-Yu Tsai; Shih-Men Tsai; Su-Chen Lee; Shu-Fen Liu
Journal:  Clin Chim Acta       Date:  2005-08       Impact factor: 3.786

5.  Low HDL levels and the risk of death, sepsis and malignancy.

Authors:  Renana Shor; Julio Wainstein; David Oz; Mona Boaz; Zipora Matas; Asora Fux; Aaron Halabe
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

Review 6.  Artifactual laboratory abnormalities in patients with paraproteinemia.

Authors:  Vivek Roy
Journal:  South Med J       Date:  2009-02       Impact factor: 0.954

7.  Artifactual measurement of low serum HDL-cholesterol due to paraproteinemia.

Authors:  Edwin O F van Gorselen; Theo Diekman; Jan Hessels; Patrick M J Verhorst; Clemens von Birgelen
Journal:  Clin Res Cardiol       Date:  2010-07-01       Impact factor: 5.460

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.